The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

(1) Background: Fidaxomicin has been shown to significantly reduce Clostridioides difficile infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question. Therefore, we cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Ronald G., Cole, Travis J., Shaw, Chip, Alvarez, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944854/
https://www.ncbi.nlm.nih.gov/pubmed/35326759
http://dx.doi.org/10.3390/antibiotics11030295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944854/
https://www.ncbi.nlm.nih.gov/pubmed/35326759
http://dx.doi.org/10.3390/antibiotics11030295

Ejemplares similares